Evidence map›Paper›PMID 35891149›Full record

ReviewVaccines2022

Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population.

Ali A Rabaan, Muhammed A Bakhrebah, Abbas Al Mutair, Saad Alhumaid, Jumana M Al-Jishi, Jehad AlSihati, Hawra Albayat, Ahmed Alsheheri, Mohammed Aljeldah, Mohammed Garout and 9 more

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 6 countries.

Ali A RabaanMolecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.ORCID 0000-0002-6774-9847
Muhammed A BakhrebahLife Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.ORCID 0000-0002-2284-3979
Abbas Al MutairResearch Center, Almoosa Specialist Hospital, Al-Ahsa 36342, Saudi Arabia.
Saad AlhumaidAdministration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0003-4552-4513
Jumana M Al-JishiInternal Medicine Department, Qatif Central Hospital, Qatif 32654, Saudi Arabia.
Jehad AlSihatiInternal Medicine Department, Gastroenterology Section, King Fahad Specialist Hospital, Dammam 31311, Saudi Arabia.
Hawra AlbayatInfectious Disease Department, King Saud Medical City, Riyadh 7790, Saudi Arabia.
Ahmed AlsheheriInfectious Disease Department, King Saud Medical City, Riyadh 7790, Saudi Arabia.
Mohammed AljeldahDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin 39524, Saudi Arabia.ORCID 0000-0001-5335-2809
Mohammed GaroutDepartment of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Wadha A AlfouzanDepartment of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.ORCID 0000-0002-4501-5316
Yousef N AlhashemDepartment of Clinical Laboratory Sciences, Mohammed AlMana College of Health Sciences, Dammam 34222, Saudi Arabia.ORCID 0000-0003-4435-3003
Salma AlBahraniInfectious Disease Unit, Specialty Internal Medicine, King Fahd Military Medical Complex, Dhahran 31932, Saudi Arabia.
Saleh A AlshamraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia.
Sultan AlotaibiMolecular Microbiology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Abdullah A AlRamadhanLaboratory and Toxicology Department, Security Forces Specialized Comprehensive Clinics, Al-Ahsa 36441, Saudi Arabia.
Hanadi N AlbashaDepartment of Infection Prevention and Control, Obeid Specialized Hospital, Riyadh 12627, Saudi Arabia.
Khalid HajissaDepartment of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia.ORCID 0000-0002-1725-6702
Mohamad-Hani TemsahPediatric Department, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-4389-9322
King Saud Medical City · SAAlfaisal University · SAFarwaniya Hospital · KWImam Abdulrahman Bin Faisal University · SAKing Abdulaziz City for Science and Technology · SAKing Fahad Specialist Hospital · SAKing Fahd Medical City · SAKing Fahd Military Medical Complex · SAKing Saud University · SAMinistry of Health · MMNajran University · SAPrincess Nourah bint Abdulrahman University · SAQatif Central Hospital · SASecurity Forces Hospital · SAUmm al-Qura University · SAUniversiti Sains Malaysia · MYUniversity of Hafr Al-Batin · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, caused by SARS-CoV-2, is one of the longest viral pandemics in the history of mankind, which have caused millions of deaths globally and induced severe deformities in the survivals. For instance, fibrosis and cavities in the infected lungs of COVID-19 are some of the complications observed in infected patients post COVID-19 recovery. These health abnormalities, including is multiple organ failure-the most striking pathological features of COVID-19-have been linked with diverse distribution of ACE2 receptor. Additionally, several health complications reports were reported after administration of COVID-19 vaccines in healthy individuals, but clinical or molecular pathways causing such complications are not yet studied in detail. Thus, the present systematic review established the comparison of health complication noted in vaccinated and non-vaccinated individuals (COVID-19 infected patients) to identify the association between vaccination and the multiorgan failure based on the data obtained from case studies, research articles, clinical trials/Cohort based studies and review articles published between 2020-2022. This review also includes the biological rationale behind the COVID-19 infection and its subsequent symptoms and effects including multiorgan failure. In addition, multisystem inflammatory syndrome (MIS) has been informed in individuals post vaccination that resulted in multiorgan failure but, no direct correlation of vaccination with MIS has been established. Similarly, hemophagocytic lymphohistiocytosis (HLH) also noted to cause multiorgan failure in some individuals following full vaccination. Furthermore, severe complications were recorded in elderly patients (+40 years of age), indicates that older age individuals are higher risk by COVID-19 and post vaccination, but available literature is not sufficient to comply with any conclusive statements on relationship between vaccination and multiorgan failure.

Indexed as

ACE2 receptorCOVID-19multiorgan failuremultisystem inflammatory syndromeSARS-CoV-2vaccination

Identifiers

PMID35891149
PMCPMC9318201
OpenAlexW4283327493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.